Cross-talk between an activator of nuclear receptors-mediated transcription and the D1 dopamine receptor signaling pathway

Nuclear receptors are transcription factors that usually interact, in a ligand-dependent manner, with specific DNA sequences located within promoters of target genes. The nuclear receptors can also be controlled in a ligand-independent manner via the action of membrane receptors and cellular signali...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology, biochemistry and behavior biochemistry and behavior, 2005-03, Vol.80 (3), p.379-385
Main Authors: SCHMIDT, Azriel, VOGEL, Robert, RUTLEDGE, Su Jane, OPAS, Evan E, RODAN, Gideon A, FRIEDMAN, Eitan
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Cell Line
Cercopithecus aethiops
COS Cells
Dopamine - pharmacology
Dopamine Antagonists - pharmacology
Dose-Response Relationship, Drug
Fundamental and applied biological sciences. Psychology
Humans
Macaca
Male
Mammary Tumor Virus, Mouse - genetics
Molecular and cellular biology
Molecular genetics
Rats
Receptor Cross-Talk - drug effects
Receptor Cross-Talk - physiology
Receptors, Dopamine D1 - agonists
Receptors, Dopamine D1 - antagonists & inhibitors
Receptors, Dopamine D1 - physiology
Signal Transduction - drug effects
Signal Transduction - physiology
Transcription Factor AP-1 - physiology
Transcription, Genetic - drug effects
Transcription, Genetic - physiology
Transcription. Transcription factor. Splicing. Rna processing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nuclear receptors are transcription factors that usually interact, in a ligand-dependent manner, with specific DNA sequences located within promoters of target genes. The nuclear receptors can also be controlled in a ligand-independent manner via the action of membrane receptors and cellular signaling pathways. 5-Tetradecyloxy-2-furancarboxylic acid (TOFA) was shown to stimulate transcription from the MMTV promoter via chimeric receptors that consist of the DNA binding domain of GR and the ligand binding regions of the PPARbeta or LXRbeta nuclear receptors (GR/PPARbeta and GR/LXRbeta). TOFA and hydroxycholesterols also modulate transcription from NF-kappaB- and AP-1-controlled reporter genes and induce neurite differentiation in PC12 cells. In CV-1 cells that express D(1) dopamine receptors, D(1) dopamine receptor stimulation was found to inhibit TOFA-stimulated transcription from the MMTV promoter that is under the control of chimeric GR/PPARbeta and GR/LXRbeta receptors. Treatment with the D(1) dopamine receptor antagonist, SCH23390, prevented dopamine-mediated suppression of transcription, and by itself increased transcription controlled by GR/LXRbeta. Furthermore, combined treatment of CV-1 cells with TOFA and SCH23390 increased transcription controlled by the GR/LXRbeta chimeric receptor synergistically. The significance of this in vitro synergy was demonstrated in vivo, by the observation that SCH23390 (but not haloperidol)-mediated catalepsy in rats was potentiated by TOFA, thus showing that an agent that mimics the in vitro activities of compounds that activate members of the LXR and PPAR receptor families can influence D1 dopamine receptor elicited responses.
ISSN:0091-3057
1873-5177
DOI:10.1016/j.pbb.2004.11.013